A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, Sonnenschein A, DeSantis DF, Kotani D, Watanabe J, Kotaka M, Mishima S, Bando H, Yamazaki K, Taniguchi H, Takemasa I, Kato T, Sangli C, Tell R, Blidner R, Yoshino T, Sasser K, Oki E, Nimeiri H.
Nakamura Y, et al. Among authors: mishima s.
Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39513962